After a brief review of the qualities of the new triphasic contraceptive preparation Trisistone and some of its advantages in comparison with the other combined contraceptive drugs the authors report on the results from the first study, carried out in our country, on the therapeutic effect of Trisistone. Thirty-eight women with various gynecological diseases were treated. The largest group was that of women with irregular bleedings. In this group the effect was not good in all women. It was found that Trisistone had limited possibilities to control irregular uterine bleedings, which most probably was connected with its comparatively low dose of steroid hormones. The side effects were comparatively slight and not quite frequently. The most frequent side effect was the occurrence of irregular bleeding in 9.5% of the treated women. The state without any side effects was improved in 30.1% of the patients. Best results were found in women with postcastration syndrome, hypoestrogenism and congenital anomalies in the development of ovaries--primary ovarian dysgenesis. Trisistone is especially suitable for substituted treatment in women with ovarian hormonal deficit.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Differential changes in appetite hormones post-prandially based on menstrual cycle phase and oral contraceptive use: A preliminary study.
Appetite
July 2024
Department of Kinesiology and Physical Education, Wilfrid Laurier University, Waterloo, Ontario, Canada. Electronic address:
This was a preliminary study that examined whether appetite regulation is altered during the menstrual cycle or with oral contraceptives. Ten naturally cycling females (NON-USERS) and nine tri-phasic oral contraceptive using females (USERS) completed experimental sessions during each menstrual phase (follicular phase: FP; ovulatory phase: OP; luteal phase: LP). Appetite perceptions and blood samples were obtained fasted, 30, 60, and 90 min post-prandial to measure acylated ghrelin, active glucagon-like peptide-1 (GLP-1), and total peptide tyrosine tyrosine (PYY).
View Article and Find Full Text PDFPortal Vein Thrombosis (PVT) Secondary to Protein C Deficiency in a Young Male.
Cureus
November 2023
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
A disorder known as portal venous thrombosis (PVT) is characterized by a partial or total obstruction of the portal vein. Although PVT is somewhat uncommon, liver illness is frequently linked to it. Cirrhosis, carcinoma of the liver, myeloproliferative neoplasms, other malignancies, the use of oral contraceptives, intestinal infections, and genetic hypercoagulable illnesses are typical risk factors.
View Article and Find Full Text PDFThe role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review.
Eur J Contracept Reprod Health Care
June 2023
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Introduction: Both Food and Drugs Administration and European Medicine Agency (EMA) approve the use of a triphasic combined oral contraceptive (COC) containing ethinyl-oestradiol (EE) and norgestimate (NGM) for acne vulgaris treatment in women requiring an effective contraception. COCs can target sebum production and may also play a role in decreasing follicular hyperkeratinisation.
Results: Specific advantages of the use of an anti-androgenic progestin such as NGM in this condition are presented in this review, including the lowest venous thrombosis risk in the COCs scenario, as established by the EMA, associated with a very satisfactory cycle control.
Association between contraceptive use and risk of lower urinary tract infection (LUTI): A case-control study.
Int J Clin Pharmacol Ther
April 2022
Aim: The aim of this study was to analyze the association between widely used contraceptive methods and the manifestation of lower urinary tract infections (LUTI) in patients treated in gynecological practices in Germany.
Materials And Methods: This study was based on IQVIA Disease Analyzer database and includes a total of 133,638 females aged between 16 and 50 years who received an initial diagnosis of LUTI including cystitis (ICD-10: N39.0, N30.
Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
Am J Obstet Gynecol
June 2022
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:
Article Synopsis
- This study investigates the link between different types of oral contraceptives and breast cancer risk, particularly focusing on specific disease subtypes.
- The research, involving over 113,000 women, reveals that current use of oral contraceptives is associated with a higher risk of invasive breast cancer, especially for those using them for more than five years.
- The findings indicate that while current users have an increased risk, former users who have stopped for more than five years show similar risks to those who have never used contraceptives, and these associations don’t vary significantly by tumor subtype.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!